| Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma studied in …STUDIED_INderived10 of 19show all (up to 200) |
|---|
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440567Phase 1 · completed Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06854159Phase 2 · recruiting Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy · condition mapped CURATED_BROADER · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850495Phase 1 · active not recruiting Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03321643Phase 1 · active not recruiting Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 19 trials mapped (10 active) | — | — | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |